Navigation Links
Lexicon Pharmaceuticals to Present at Bio InvestorForum
Date:10/4/2007

THE WOODLANDS, Texas, Oct. 4 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the BIO InvestorForum at The Palace Hotel in San Francisco, California on Thursday, October 11, 2007 at 11:00 a.m. Pacific Time.

A live webcast of Lexicon's presentation may be accessed on its corporate website at http://www.lexpharma.com. An archived version of the webcast will be available on the website through October 19, 2007.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has clinical programs underway for such areas of major unmet medical need as irritable bowel syndrome and cognitive disorders. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... New York (PRWEB) July 22, 2014 ... world. The heat produced by controlled fission chain reaction ... This steam pressure is used to drive a power- ... approximately 19% of the world’s total electricity production. Nuclear ... to several under construction, planned and proposed nuclear reactor ...
(Date:7/22/2014)... 22, 2014 The DNA Spectrum ... concise visual representation of history, migration, and culture. ... regaled by family history stories stemming from Europe. His ... "old country." Pictures and 8mm home movies painted an ... the family, and Steve ordered a test from DNA ...
(Date:7/22/2014)... SHENZHEN , Kina, 22. juli 2014 /PRNewswire/ ... et datterselskab af BGI, verdens største genomics-organisation, annoncerede ... exome-sekvenseringstjeneste baseret på Complete Genomics brancheførende platform. ... for at levere patenterede sekvenseringsteknologier med 99,999 % ... blev købt af BGI i 2013. Mere end ...
(Date:7/22/2014)... July 22, 2014 Hussey Copper , ... 29 antimicrobial copper announces Pullman Regional Hospital,s conversion ... EPA-registered antimicrobial solid touch surface, at a nominal cost.  ... MRSA, E-coli and other bacteria within 2 hours of exposure ... against bacteria and infectious diseases in its facilities. ...
Breaking Biology Technology:Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 2DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 4BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3
... Pafuramidine on Clinical Hold ... Schedule Zensana(TM) ... N.J., Dec. 28 Par,Pharmaceutical Companies, Inc. (NYSE: ... the,development status of its three, in-licensed, proprietary pipeline,products: ...
... ... merger, SOUTH SAN FRANCISCO, Calif., Dec. ... approved the proposed reverse split of its common stock by,a margin of nearly ... VaxGen to reverse split its stock in a ratio of 4,5, or 6 ...
... Program: Discriminating Real Science from Faux Science, ... recent meeting of,the Arizona Pain Society, Dominion Diagnostics ... of Urine Drug Testing:,Which Test, Which Patient and ... Robert Barkin, Pharm.D, MBA, FCP, DAAPM. Dr.,Barkin is ...
Cached Biology Technology:Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 2Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 3Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 4Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 5VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal 2VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal 3VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal 4Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics 2
(Date:7/21/2014)... there are reasons mammoths and mastodons could have been ... research from the University of Cincinnati, the famously fuzzy ... before it was trendy at the end of ... Crowley, an assistant professor of geology and anthropology, shows ... likely were year-round residents and not nomadic migrants as ...
(Date:7/21/2014)... to conserve water and save on your utility bill? ... published in the current issue of the journal ... The Most Effective Actions U.S. Households Can Take to ... use substantially by simple actions such as installing more ... While the suggestions may be familiar, the researchers are ...
(Date:7/21/2014)... Diego School of Medicine-led study suggests that parents of ... health consequences of childhood weight gain or the importance ... a healthy weight. , The study is published online ... and Dietetics . , "Parents have a hard time ... lead author Kyung Rhee, MD, and an assistant adjunct ...
Breaking Biology News(10 mins):Mammoth and mastodon behavior was less roam, more stay at home 2Mammoth and mastodon behavior was less roam, more stay at home 3Researchers provide guide to household water conservation 2Researchers provide guide to household water conservation 3Parents rank their obese children as 'very healthy' 2
... release is available in German . , ... by the Alfred Wegener Institute for Polar and Marine ... for the first time. Polarstern left the port of ... southern course and is located right in the Northwest ...
... the Wildlife Conservation Society, Smithsonian Tropical Research Institute, National ... a new species of fisha grouper that reaches more ... 1,000 pounds. This newly discovered species can be found ... Was the massive fish hiding among the ...
... New phase 2 data published today in The ... demonstrates activity in nonsense-mutation cystic fibrosis (CF). The ... significant improvements in the chloride channel function of patients ... the Hadassah Hebrew University Hospital in Jerusalem, Israel and ...
Cached Biology News:RV Polarstern on its way to East Siberian Sea 2RV Polarstern on its way to East Siberian Sea 3Genetics reveals big fish that almost got away 2PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet 2PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet 3
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
NATIVE, ENZYME PORCINE TRYPSIN...
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
EDTA, disodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99.0-101.0%, nuclease-free.Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemi...
Biology Products: